INDIBA® is an excellent tool to complement physiotherapy to effectively treat a range of musculoskeletal (MSK) conditions, which involves bones, joints, muscles, tendons, and ligaments. It accelerates rehabilitation and leads to improved outcome scores for chronic ailments. These results are obtained due to its efficacy in reducing pain, controlling swelling, improving tissue functionality and elasticity, and increase in vascularity.
INDIBA® is used for the management of conditions that are currently difficult to treat with medical prescriptions or other types of treatments. Osteoarthritis is a common degenerative condition of the joints that results in stiffness and pain.
Clinical studies have shown that INDIBA® significantly reduces pain for up to 3 months and improves joint function in patients with knee osteoarthritis compared to patients that only undergo physical therapy1. Many people suffer from different types of chronic back pain (lumbago, sciatica, herniated disks).
INDIBA® alongside physiotherapy rehabilitation is very efficient in managing, reducing pain, and improving mobility, thus reducing disability2,3. Moreover, INDIBA® significantly reduces pain and oedema evolution during the first days after surgery4.
MSK conditions that can be treated:
1 Kumaran, B. & Watson, T. Treatment using 448kHz capacitive resistive monopolar radiofrequency improves pain and function in patients with osteoarthritis of the knee joint: a randomised controlled trial. Physiotherapy 105, 98-107, doi:10.1016/j.physio.2018.07.004 (2019).
2 Takahashi, K. et al. Clinical Effects of Capacitive Electric Transfer Hyperthermia Therapy for Lumbago. The Journal of Physical Therapy Science 11, 6 (1999).
3 Takahashi, K. et al. Clinical Effects of Capacitive Electric Transfer Hyperthermia Therapy for Cervico-OmoBrachial Pain. The Journal of Physical Therapy Science 12, 5 (2000).
4 Terranova, A. et al. Monopolar capacitive resistive radiofrequency 448 kHz in the post-surgical treatment of femoral fracture. INDIBA Revitalizing lives 3, 2 (2008).